Journal Name

ARTICLE

Concise asymmetric syntheses of novel phenanthroquinolizidines

Cintia Anton-Torrecillas,[a] María Isabel Loza,[b] and José Brea[b] and Jose C. Gonzalez-Gomez*[a]

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

The first preparation of enantioenriched phenanthroquinolizidines with a quaternary center at C_{14a} was accomplished in seven steps from readily available starting materials. Key steps were an efficient dynamic kinetic allylation of a diastereomeric mixture of chiral *tert*-butylsulfinyl ketimines and the construction of piperidine E ring by rhodium catalyzed hydroformylation. The Stevens rearrangement of the corresponding N-benzyl derivatives took place smoothly, allowing the installation of a benzyl moiety at C_9 in a *trans* relationship with the methyl group. The cytoxycity of the prepared phenanthroquinolizidines was evaluated against different human cancer cell lines.

Introduction

Compared with synthetic drugs, natural product derivatives show lower toxicity and easier decomposition, which is also more environmentally friendly.[1] These advantages, in addition to their unique mode of action, are responsible for the growing interest in the synthesis and biological evaluation of natural based compounds. Among natural alkaloids are a small group of phenanthroquinolizidines (e.g. cryptopleurine and boehmeriasin A in Figure 1) which are produced by the *Lauraceae*, *Vitaceae*, and *Urticaceae* family of plants.[2] Remarkably, these compounds exhibit very high cytotoxic activities with IC_{50} in the nanomolar range, being in some cases more potent than taxol.[3] Moreover, they have shown higher antiproliferative activity than their structurally related phenanthroindolizidine alkaloids.[4] It is reported that these alkaloids and their analogs display a wide range of biological activities and they are currently being used as lead compounds in order to optimize these activities.[5]

Some natural phenanthroindolizidine alkaloids bearing a methyl group at the 13a-position (e.g. hypoestestatin 1 and 2, Figure 1) have been identified as extremely potent antitumor agents.[6] Recent studies have shown that the inclusion of a substituent next to the nitrogen atom disrupts the molecular



Fig.1 Some phenantroizidine alkaloids

planarity, decreasing the crystal packing energy and therefore increasing their water solubility.[7] It is worth to mention that enhance the hydrophilicity of these compounds is an established strategy to improve their bioavailability, so as to lower their blood-brain barrier permeability, which potentially might minimize their CNS toxicity.[8] In this context, the asymmetric syntheses of some 13a-substituted phenanthroindolizidine alkaloids have been successfully accomplished, using proline derivatives as chiral building blocks.[9] However, to our best knowledge, the enantioselective synthesis of structurally related phenanthroquinolizidines with a quaternary center at C_{14a} remains unexplored. Given the unique biological activities of 7-methoxycryptopleurine,[10] we considered that this compound would offers a good platform to explore this strategy.

Results and discussion

We describe herein a protocol for the asymmetric preparation of 7-(*R*)-and (*S*)-methoxy-14a-methylcryptopleurine,[11,12] as well as the first regio- and diastereoselective Stevens rearrangement of the corresponding N-benzyl ammonium salt.

[a] *Departamento de Química Orgánica, Facultad de Ciencias and Instituto de Síntesis Orgánica (ISO), Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain. E-mail: josecarlos.gonzalez@ua.es*

[b] *Address Grupo de Investigación Biofarma. USEF screening platform. Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidad de Santiago de Compostela. Avda de Barcelona s/n. Santiago de Compostela, Spain.*

†Electronic Supplementary Information (ESI) available: Copies of ^1H and ^{13}C NMR spectra for compounds **2**-**10**, and HPLC traces used for the determination of enantiomeric ratios of compounds **8** and **10**. The dose-response curves for cytotoxic compounds against four cancer cell lines are included, as well as general information related with the cytotoxicity assays. See DOI: 10.1039/x0xx00000x

Journal Name

ARTICLE



Scheme 1 Retrosynthetic analysis of the target molecule.



Scheme 2 Syntheses of phenanthroquinolizidines **8** and ***ent*-8**.

In our retrosynthetic analysis (Scheme 1), we envisaged that a benzyl group could be diastereoselectively installed at C-9 by N-benzylation of the corresponding phenanthroquinolizidine, followed by Stevens rearrangement. The synthesis of this scaffold was planned by building ring D in the last step using Pictet-Spengler annulation, while ring E could be formed by hydroformylation of the corresponding homoallylic amine.[13] Importantly, the chiral quaternary center was anticipated to be formed by allylation of the chiral *tert*-butylsulfinyl ketimine derived from the corresponding methylketone. As outlined in Scheme 1, the target molecule was traced back to: 9-bromo-2,3,6,7-tetramethoxyphenanthrene, chiral *tert*-

butylsulfinamide, allylindium reagent, formaldehyde and isoprenylacetate; all of them commercially or easily available starting materials.

The realization of our synthetic plan is outlined in Scheme 2. The palladium catalyzed cross coupling of isoprenyl acetate with the readily available 9-bromo-2,3,6,7-tetramethoxyphenanthrene[14] was efficiently promoted by tributyltin methoxide to afford the desired methylketone **2** in high yield.[15] Condensation of ketone **2** with (*Ss*)-*tert*-butylsulfinamide afforded the corresponding ketimine as a 4:1 mixture of *E/Z* isomers-**3**, which upon addition of *in-situ* formed allylindium reagent furnished the expected chiral amine **4** with an α-quaternary center as a single isomer (>98:2 dr according to NMR).[16] This efficient dynamic kinetic transformation of *tert*-butylsulfinyl ketimines to homoallylic amines has been previously reported[17,18] and it is worth mentioning that the one-pot indium mediated direct aminoallylation of the methyl ketone- a procedure that we have previously developed and successfully used in our group[19]- gave significantly lower conversion in this case (up to 30 %). Our next key step was the rhodium catalyzed linear hydroformylation to build ring E as an enamine. Given our previous experience with this strategy,[13] the sulfinyl group was replaced by an N-Boc protecting group. We thus submitted compound **5** to rhodium(I) catalyzed hydroformylation with formalin, using two different phosphane ligands (BIPHEP and NiXantphos). The characteristics of this hydroformylation protocol are unique because the syngas (CO/H_2) is conveniently substituted by formaldehyde, with excellent linear selectivity.[20] Under these conditions, the formation of the corresponding terminal aldehyde was followed by *in-situ* cyclization to furnish the protected enamine **6**. We were pleased to observe that by only increasing the loading of rhodium catalyst from 1 mol % to 3 mol %, the isolated yield of compound **6** increased from 61% to 90%. Catalytic hydrogenation of enamine **6** using Adams's catalyst, followed by acidic removal of the Boc group and Pictet Spengler cyclomethylenation under standard conditions (formalin, HCl, EtOH, 100 ºC),[21] allowed the preparation of the target compound **8** with very good overall yield. The same synthetic sequence was applied to obtain ***ent*-8** from (*Rs*)-*tert*-butylsulfinamide with similar efficiency in terms of isolated yields. Chiral HPLC analysis of both enantiomers (**8** and ***ent*-8**) shows that racemization did not take place over the synthetic sequence (96:4 er, see ESI).

During the optimization of the biological activities of phenanthroquinolizidines, diverse substituted compounds have been reported in the literature.[4b, 10d, 22] However, substitutions at C-9 of this skeleton remain scarce.[23] With this in mind, we decided to explore the Stevens rearrangement[24] of the N-benzyl isoquinolinium salts **9** and ***ent*-9**, which were efficiently prepared using conventional methods (Scheme 3). It is worth noting that the NMR data (^1H and ^{13}C) obtained for these compounds is consistent with a single diastereoisomer. In contrast with other related alkaloids that contains the quinolizidine moiety (e.g. berbines),[25] inversion at the N bridgehead of the starting material is unlikely in phenanthro-



Scheme 3 Regio-and Stereoselective Stevens Rearrangement of compound **9**

quinolizidines and the adjacent methyl group should stabilize the *trans* isomer. It is generally assumed that, either by formation of an iminium ion or via recombination of radical pairs in solvent-cage,[26] the Stevens rearrangement is suprafacial. Given that only *trans*-isoquinolinium isomer **9** seems to be present, deprotonation at the benzylic C-9 position, followed by the rearrangement should only afford ***trans*-10** compound. Given the good results obtained in the synthesis of 8-benzylberbines, by using *in-situ* prepared dimsyl sodium solution at room temperature for the Stevens rearrangement, we adopted these conditions and compound **10** was obtained in a moderate yield. [27] Although we were not able to identify the by-products formed in this reaction, we reasoned that hydrogens at β-positions (H_{12eq}, H_{14eq} and H_{15eq}) make Hofmann eliminations competitive pathways. Importantly, a significant H,H-n.O.e was observed between the Me at C_{14a} and H_9 of compound **10** (see SI), confirming the presumed *trans*-configuration for this compound. Using the same method, ***ent*-9** was transformed into ***ent*-10**. Having prepared both enantiomers, the enantiomeric purity of the samples was determined by chiral HPLC analysis, being above 90% ee in both cases.

Compounds **8**, **9**, **10** and their enantiomers were tested against four human cancer cell lines, using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltretrazolium bromide) method and CDDP [*cis*-diaminedichloroplatinum (II)] as positive control. The IC_{50} values were determined from the corresponding inhibition/concentration curves (see SI) when more than 50% cellular growth inhibition was achieved at 100 μM and the results are shown in Table 1. The best results were obtained for compound **8**, with the (*R*)-configuration (as in natural cryptopleurine), against human breast cancer cell lines (MCF-7) and with leukemia cells (HL-60). The potency of this compound was 20-fold (for MCF-7) or 10-fold (for HL-60) superior to that its enantiomer, but it was significantly lower than the one of the (*R*)-7-methoxycryptopleurine, without a

methyl group at C_{14a}.[13] Unfortunately, when the benzyl group was attached to the nitrogen atom and then rearranged to C_9, the obtained compounds showed poorer cellular growth inhibition.

Table 1 Cytotoxicity of compounds evaluated.

	IC50 (μM)[a]			
Compounds	MCF-7[b]	NCI-H460[c]	HL-60[d]	NCI/ADR-RES[e]
CDDP	16 ± 1	5.7 ± 0.2	8.3 ± 0.2	6.3 ± 0.2
8·HCl	1.1 ± 0.1	34f ± 7	0.51 ±0.02	69f ± 26
ent-8·HCl	21 ± 2	42 ± 1	4.9 ± 0.1	26 ± 1
9	80[f] ± 14	n.d[g]	65[f] ± 5	n.d[g]
ent-9	76[f] ± 7	393[f] ± 168	n.d[g]	n.d[g]
10	35[f] ± 1	n.d[g]	80[f]±3	n.d[g]
ent-10	36 ± 1	n.d[g]	n.d[g]	n.d[g]

[a] Average of three assays each. [b] MCF-7 = human breast carcinoma. [c] NCI-H460 = human lung carcinoma. [d] HL-60 = human promyelocytic leukemia. [e] NCI-ADR-RES= drug-resistant human ovarian adenocarcinoma. [f] Extrapolated values from an incomplete concentration-response curve (see SI). [g] Not determined.

Conclusions

We have developed a seven step procedure to prepare enantioenriched 14a-methyl-7-methoxycryptopleurine in 18-21% overall yield from readily available starting materials. Salient features of the synthetic procedure are: (a) the straightforward formation of methyl ketone **2**; (b) the efficient dynamic kinetic allylation of *tert*-butylsulfinyl ketimines **3** (4:1 *E*/*Z* mixture) to obtain compound **4** as a single isomer; and (c) a rhodium catalyzed linear hydroformylation with formalin that allows construction of ring E in excellent yield. N-benzylation of phenanthroquinolizidine **8**, followed by Stevens rearrangement at room temperature allows for regio- and stereoselective placement of a benzyl group and C_9. The cytotoxic evaluation of compound **8** (***ent*-8**) indicates that the introduction of a methyl group at C_{14a} decreases the potency of 7-methoxycryptopleurine. In addition, the introduction of a benzyl group at C_9 of the same scaffold had a more significant negative impact on its cytotoxicity. The synthetic route developed herein opens the access to enantioenriched phenathroquinolizidines with a quaternary center at C_{14a} and *trans*-C_9 benzyllic derivatives, which hopefully can display different biological activities.

Experimental

General information

TLC was performed on silica gel 60 F_{254}, using aluminium plates and visualized by exposure to ultraviolet light. Flash chromatography was carried out on handpacked columns of silica gel 60 (230 – 400 mesh). Optical rotations were measured using a polarimeter with a thermally jacketted 5 cm cell at approximately 20 ºC and concentrations (c) are given in g/100 mL. Infrared analysis was performed with a spectrophotometer equipped with an ATR component; wavenumbers are given in cm^{-1}. HRMS analyses were carried out using the Electron Impact (EI) mode at 70 eV or by Q-TOF using Electro Spray Ionization (ESI) mode. HPLC analyses were performed using a Chiralpak IB column for enantiomeric ratios. ^{1}H NMR spectra were recorded at 300 or 400 MHz for ^{1}H NMR and 75 or 100 MHz for ^{13}C NMR, using $CDCl_3$ as the solvent and TMS as an internal Standard (0.00 ppm). ^{13}C NMR spectra were recorded with ^{1}H-decoupling at 100 MHz and referenced to $CDCl_3$ at 77.16 ppm. DEPT-135 experiments were performed to assign CH, CH_2 and CH_3.

1-(2,3,6,7-tetramethoxyphenanthren-9-yl)propan-2-one (2). A dry flask was charged with 9-bromo-2,3,6,7-tetramethoxyphenanthrene[14] (391 mg, 1.04 mmol), $Pd(OAc)_2$ (11.67 mg, 0.05 mmol, 5 mol %) and tri-*ortho*-tolylphosphine (33 mg, 0.10 mmol). The reaction mixture was evacuated and backfilled with argon (3 cycles) before adding toluene (1.21 mL), tributyltin methoxide (463 μL, 1.60 mmol) and isoprenyl acetate (174 μL, 1.57 mmol). The reaction mixture was stirred while heating at 100 ºC during 6 h. The reaction mixture was cooled down to room temperature and diluted with EtOAc (2.0 mL) and 4 M aqueous potassium fluoride solution (1.5 mL) and stirred for 15 min, before being filtered through a short pad of Celite, washed with EtOAc and concentrated under vacuo. The residue was purified by flash chromatography (6:4 to 1:1 hexane/EtOAc), recovering the starting material (98 mg, 25%) and obtaining the desired product as a ochre yellow solid (274 mg, 74%): R_f 0.24 (1:1 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.83 (s, 1H), 7.78 (s, 1H), 7.53 (s, 1H), 7.28 (s, 1H), 7.21 (s, 1H), 4.12 (s, 3H), 4.12 (s, 3H), 4.06 (s, 2H), 4.04 (s, 3H), 4.02 (s, 3H), 2.09 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) *δ* 208.0 (*C*), 149.5 (*C*), 149.2 (*C*), 149.1 (*C*), 127.3 (*C*), 126.6 (*C*H), 126.34 (*C*), 125.6 (*C*), 125.1 (*C*), 124.4 (*C*), 108.2 (*C*H), 105.1 (*C*H), 103.5 (*C*H), 102.9 (*C*H), 56.2 (*C*H_3), 56.19 (*C*H_3), 56.0 (*C*H_3), 50.8 (*C*H_2), 28.7 (*C*H_3); HRMS (ESI) calcd for $C_{21}H_{23}O_5$ 355.1545, found 355.1549.

(*E*/*Z*,*S*$_S$)-*N*-(*tert*-Butylsulfinyl)-1-(2,3,6,7-tetramethoxy-phenanthren-9-yl)propan-2-imine (3). To a dry flask were sequentially added (*S*$_S$)- *tert*-butylsulfinamide (1.83 mg, 1.50 mmol), compound **2** (531 mg, 1.5 mmol) and THF (3.0 mL), followed by $Ti(OEt)_4$ (675 μL, 3.0 mmol). The reaction mixture was stirred overnight at 65 ºC. After cooled to room temperature, it was carefully added over a stirring mixture of 4:1 EtOAc/brine. The resulted white suspension was filtered through a short pad of Celite, washed with EtOAc and concentrated to dryness. The residue was purified by flash chromatography (4:6 to 3:7 hexane/EtOAc,), affording the imine as a yellow foam solid (401 mg, 76%, 80:20 *E*/*Z*): R_f 0.23 (3:7 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) *δ* 7.83 (s, 1H), 7.78 (s, 1H), 7.55 – 7.48 (m, 1H), 7.47 – 7.42 (m, 1H), 7.23 – 7.19 (m, 1H), 4.13 (s, 6H), 4.04 (s, 3H), 4.02 (s, 3H), 2.29 (s, 1.84H, *E*-isomer), 2.09 (s, 0.36H, *Z*-isomer), 1.23 (s, 1.31H, *Z*-isomer), 1.20 (s, 5.69H, *E*-isomer); ^{13}C NMR (75 MHz, $CDCl_3$) *δ* 149.5 (*C*), 149.2 (*C*), 149.1 (*C*), 149.0 (*C*), 128.1 (*C*), 126.6, 126.2 (*C*), 125.8 (*C*), 125.1 (*C*), 124.4 (*C*), 108.2 (*C*H), 105.6 (*C*H), 103.5 (*C*H), 102.9 (*C*H), 56.6 (*C*), 56.3 (2*C*H_3), 56.2 (*C*H_3), 56.1 (*C*H_3), 49.3 (*C*H_2), 22.3 (*C*H_3), 21.8 (*C*H_3); HRMS (ESI) calcd for $C_{25}H_{31}NO_5NaS$ 480.1821, found 480.1827.

(*ent*-3). It was prepared from (*R*$_S$)- *tert*-butylsulfinamide (228.7 mg, 1.89 mmol), following the same procedure described for

the preparation of **3**, with similar yield (571 mg, 66 %). It was obtained as a 4:1 *E/Z* mixture with identical characterization data than compound **3**.

(1*R*,S_S)-*N*-(*tert*-Butylsulfinyl)-1-allyl-1-methyl-2-[2,3,6,7-tetramethoxyphenanthren-9-yl]-ethylamine (4). To a mixture of imine **3** (505 mg, 1.10 mmol) in dry THF (2.2 mL) were sequentially added indium powder (159 mg, 1.38 mmol) and allyl bromide (144 μL, 1.66 mmol). The reaction mixture was stirred overnight under argon atmosphere at 65 ºC. Afterwards, the mixture was filtered through a short pad of Celite, washed with EtOAc and concentrated. The residue was purified by flash chromatography (hexane/EtOAc 3:7) to obtain the desired product as a white amorphous solid (398 mg, 72%, >98:2 dr according to ^{1}H-NMR[16]): $[\alpha]^D_{20}$ −3.0 (c 6.56, $CHCl_3$); R_f 0.18 (3:7 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) *δ* 7.80 (s, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H), 7.18 (s, 1H), 6.09 – 5.92 (m, 1H), 5.29 (d, *J* = 3.2 Hz, 1H), 5.23 (s, 1H), 4.11 (s, 3H), 4.11 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.77 (s, 1H), 3.43 (d, *J* = 14.2 Hz, 1H), 3.28 (d, *J* = 14.2 Hz, 1H), 2.66 (d, *J* = 7.3 Hz, 2H), 1.23 (s, 3H), 1.07 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) *δ* 149.3 (*C*), 149.1 (*C*), 148.9 (*C*), 148.6 (*C*), 133.7 (*C*H), 128.9 (*C*), 127.9, 126.6 (*C*), 126.1 (*C*), 125.1 (*C*), 123.9 (*C*), 120.1 (*C*), 108.1 (*C*H), 105.9 (*C*H), 103.5 (*C*H), 102.8 (*C*H), 59.4 (*C*), 56.8 (*C*), 56.3 (2*C*H_3), 56.2 (*C*H_3), 56.1 (*C*H_3), 46.0(*C*H_2), 42.2 (*C*H_2), 26.5 (*C*H_3), 22.8 (*C*H_3); HRMS (ESI) calcd for $C_{28}H_{38}NO_5S$ 500.2471, found 500.2478.

(*ent*-4). It was prepared from ***ent*-3** (925 mg, 2.02 mmol), following the same procedure described for the preparation of **4**, with better yield (819 mg, 81 %) and identical characterization data**,** except for the optical rotation: $[\alpha]_D^{20}$ + 6 (c 4.13, $CHCl_3$).

(2*R*)-*tert*-Butyl-(2-methyl-1-(2,3,6,7-tetramethoxy-phenanthren-9-yl)pent-4-en-2-yl)carbamate (5). To a solution of compound **4** (313 mg, 0.76 mmol) in MeOH (7.6 mL) was added a solution of 4 M HCl in Dioxane (0.76 mL, 3.04 mmol) at 0 ºC. The reaction mixture was stirred 1.5 h at 25 ºC and then was concentrated to dryness. The residue was dissolved in CH_2Cl_2 (7.6 mL) and after cooled down the solution to 0 ºC, a 2 M aqueous solution of NaOH (7.6 mL) and Boc_2O (188.1 mg, 0.84 mmol) were sequentially added. The mixture was stirred under argon atmosphere at 25 ºC during 2.5 h. The mixture was extracted with CH_2Cl_2 (3 x 20 mL), the collected organic layers were washed with brine (5 mL), dried over $MgSO_4$ and concentrated to dryness. The crude product was purified by flash chromatography (7:3 hexane/EtOAc) to obtain the desired product as a white amorphous solid (286 mg, 76%): $[\alpha]_D^{20}$ −18 (c 6.83, $CHCl_3$); R_f 0.20 (7:3 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) *δ* 7.82 (s, 1H), 7.78 (s, 1H), 7.71 (s, 1H), 7.43 (s, 1H), 7.15 (s, 1H), 5.97 – 5.78 (m, 1H), 5.21 – 5.05 (m, 2H), 4.44 (s, 1H), 4.13 (s, 3H), 4.12 (s, 3H), 4.09 (s, 3H), 4.02 (s, 3H), 3.69 – 3.59 (m, 1H), 3.41 (d, *J* = 14.1 Hz, 1H), 2.87 (dd, *J* = 13.3, 7.3 Hz, 1H), 2.34 (dd, *J* = 13.7, 7.4 Hz, 1H), 1.49 (s, *J* = 10.3 Hz, 9H), 1.18 (s, 3H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 154.7 (*C*), 149.2 (*C*), 148.9 (*C*), 148.8 (*C*), 148.5 (*C*), 134.1 (*C*H), 130.2 (*C*), 127.1 (*C*H), 127.0 (*C*), 126.2 (*C*), 124.9 (*C*), 123.8 (*C*), 118.9 (*C*H_2), 108.0 (*C*H), 106.6 (*C*H), 103.2 (*C*H), 102.9 (*C*H), 78.9 (*C*), 56.4 (*C*H_3), 56.3 (*C*H_3), 56.1 (*C*H_3), 55.9 (*C*H_3), 43.4 (*C*H_2), 40.1 (*C*H_2), 28.7 (*C*H_3), 25.3 (*C*H_3); HRMS (ESI) calcd for $C_{29}H_{37}NO_6Na$ 518.2519, found 518.2523.

(*ent*-5). It was prepared from ***ent*-4** (819 mg, 1.64 mmol), following the same procedure described for the preparation of **5**, with similar yield (568 mg, 70%) and identical characterization data**,** except for the optical rotation: $[\alpha]_D^{20}$ + 15 (c 7.50, $CHCl_3$).

(2*R*)-*tert*-Butyl-2-methyl-2-((2,3,6,7-tetramethoxy-phenanthren-9-yl)methyl)-3,4-dihydropyridine-1(2H)-carboxylate (6). To a pressure tube were sequentially added $[RhCl(cod)]_2$ (6.92 mg, 0.014 mmol), BIPHEP (14.97 mg, 0.028 mmol), NiXantphos (15.80 mg, 0.028 mmol) and toluene (2.8 mL). The system was then evacuated and filled back with argon before compound **5** (232 mg, 0.468 mmol) and aqueous formalin (37%, 0.3 mL, 12.65 mmol) were added. The reaction mixture was deoxygenated via three cycles of freeze-pump and thaw under argon atmosphere and heated to 90 ºC. The mixture was stirred for 40 h at the same temperature and then left to reach room temperature, before being concentrated and purified by flash chromatography (hexane/EtOAc 7:3) to obtain the desired product as a white amorphous solid (213 mg, 90 %): $[\alpha]_D^{20}$ − 21 (c 6.86, $CHCl_3$); R_f 0.21 (7:3 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) *δ* 7.95 (s, 1H), 7.81 (s, 1H), 7.78 (s, 1H), 7.37 (s, 1H), 7.16 (s, 1H), 6.93 (d, *J* = 8.6 Hz, 1H), 5.00 – 4.91 (m, 1H), 4.14 (s, 3H), 4.12 (s, 3H), 4.12 (s, 3H), 4.04 (s, 3H), 3.97 (s, 1H), 3.08 (d, *J* = 14.0 Hz, 1H), 2.45 – 2.27 (m, 1H), 2.17 – 1.95 (m, 2H), 1.80 – 1.65 (m, 1H), 1.45 (s, 3H), 1.26 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) *δ* 152.7 (*C*), 149.0 (*C*), 148.9 (*C*), 148.8 (*C*), 148.6 (*C*), 131.0 (*C*), 127.5 (*C*), 127.4 (*C*H), 126.6 (*C*H), 126.2 (*C*), 124.8 (*C*), 123.9 (*C*), 108.0 (*C*H), 107.1 (*C*H), 104.3 (*C*H), 103.0 (*C*H), 102.9 (*C*H), 80.5 (*C*), 58.3 (*C*), 56.3 (*C*H_3), 56.2 (*C*H_3), 56.1 (*C*H_3), 56.0 (CH_3), 37.6 (CH_2), 35.9 (CH_2), 28.2 (CH_3), 25.9 (CH_3), 19.2 (CH_2); HRMS (ESI) calcd for $C_{30}H_{37}NO_6Na$ 530.2519, found 530.2510.

(*ent*-6). It was prepared from ***ent*-5** (473 mg, 0.95 mmol), following the same procedure described for the preparation of **6**, with similar yield (353 mg, 82 %) and identical characterization data**,** except for the optical rotation: $[\alpha]_D^{20}$ + 27 (c 4.6, $CHCl_3$).

(*R*)-*tert*-Butyl-2-methyl-2-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)piperidine-1-carboxylate (7). A dry flask was charged with compound **6** (93 mg, 0.18 mmol), PtO_2 (83% content Pt, 10.0 mg, 0.04 mmol) and a mixture of EtOH/AcOH (3.4 mL : 1.4 mL). The flask was connected to a balloon of hydrogen through a three-ways valve and the reaction mixture was put under hydrogen atmosphere (1 atm) after 3 cycles of freeze-pump and thaw. The resulting suspension was stirred at 25 °C for 24 h, and then was filtered throught Celite and washed with EtOAc (3 x 15 mL). The organic solution was concentrated to dryness and the desired product was obtained as white amorphous solid (90 mg, > 99%): $[\alpha]_D^{20}$ +16 (c 7.90, $CHCl_3$); R_f 0.21 (7:3 hexane/EtOAc); ^{1}H NMR (300 MHz, $CDCl_3$) *δ* 7.95 (s, 1H), 7.83 (s, 1H), 7.79 (s, 1H), 7.38 (s, 1H), 7.15 (s, 1H), 4.13 (s, 6H), 4.12 (s, 3H), 4.04 (s, 3H), 3.86 – 3.71 (m, 2H), 3.43 (d, J = 14.0 Hz, 1H), 3.11 – 2.96 (m, 1H), 1.98 – 1.84 (m, 1H), 1.77 – 1.57 (m, 4H) 1.48 (s, 13H); ^{13}C NMR (75 MHz, $CDCl_3$) *δ* 155.9 (*C*), 149.0

(*C*), 148.9 (*C*), 148.79 (*C*), 148.5 (*C*), 131.3 (*C*), 127.5 (*C*), 126.5 (*C*H), 126.3 (*C*), 124.9 (*C*), 123.8 (*C*), 108.1 (*C*H), 107.3 (*C*H), 103.1 (*C*H), 103.0 (*C*H), 79.3 (*C*), 59.2 (*C*), 56.3 (2*C*H_3), 56.1 (*C*H_3), 56.0 (*C*H_3), 41.4 (*C*H_2), 38.2 (*C*H_2), 35.6 (*C*H_2), 28.7 (*C*H_3), 26.3 (*C*H_3), 23.3 (*C*H_2), 17.6 (*C*H_2); HRMS (ESI) calcd for $C_{30}H_{39}NO_6Na$ 532.2675 found 532.2663.

(*ent*-7). It was prepared from ***ent*-6** (370 mg, 0.73 mmol), following the same procedure described for the preparation of **7**, with similar yield (568 mg, >99%) and identical characterization data**,** except for the optical rotation: $[\alpha]_D^{20}$ – 20 (c 2.42, $CHCl_3$).

(*R*)-2,3,6,7-tetramethoxy-14a-methyl-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline (8). To a solution of compound **7** (67 mg, 0.16 mmol) in MeOH (2.4 mL) at 0 ºC was added concentrated HCl (12 M, 0.5 mL) and the mixture was stirred for 24 h at room temperature. At this point the solvent was replaced by EtOH (4.5 mL), followed by the sequential addition of aqueous formaldehyde (37%, 0.83 mL) and concentrated HCl (12 M, 0.12 mL). The reaction mixture was put under argon atmosphere, protected from light irradiation and stirred at 90 ºC during 72 h. After cooled to room temperature, the mixture was concentrated under vacuum and the residue was distributed into CH_2Cl_2 (10 mL) and 2 M aqueous solution of NaOH (5 mL). The aqueous phase was extracted with CH_2Cl_2 (3 x 10 mL) and washed with brine (5 mL), dried over Na_2SO_4, and concentrated to dryness. Purification by flash column chromatography (7:3 hexane/(3:1 EtOAc/EtOH with 2% NH_4OH)) afforded the desired product as a pale yellow solid (50 mg, 74%): $[\alpha]_D^{20}$ – 52 (c 5.84, MeOH); R_f 0.19 (7:3, hexane/(3:1 EtOAc/EtOH with 2% NH_4OH)); 96:4 er according to chiral HPLC analysis [t_R (minor) 16.69 min, t_R (major) 18.95 min, see ESI for details]; ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.85 (s, 2H), 7.30 (s, 1H), 7.16 (s, 1H), 4.18 (br. d, *J* = 16.2 Hz, 1H), 4.12 (s, 3H), 4.12 (s, 3H), 4.08 (s, 3H), 4.06 (s, 3H), 3.94 (br. d, *J* = 15.4 Hz, 1H), 3.09 (br. d, *J* = 15.8 Hz, 1H), 2.98 – 2.84 (m, 2H), 2.74 – 2.58 (m, 1H), 1.91 – 1.64 (m, 6H), 1.06 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 148.8 (2*C*), 148.6 (*C*), 148.5 (*C*), 125.9 (*C*), 124.8 (*C*), 124.2 (*C*), 124.1 (*C*), 123.8 (*C*), 123.4 (*C*), 104.0 (*C*H), 103.7 (*C*H), 103.6 (*C*H), 103.2 (*C*H), 56.2 (*C*H_3), 56.1 (*C*H_3), 52.1 (*C*), 51.9 (*C*H_2), 50.3 (*C*H_2), 40.2 (*C*H_2), 39.7 (*C*H_2), 26.4 (*C*H_2), 20.8 (*C*H_2), 14.3 (*C*H_3); HRMS (ESI) calcd for $C_{26}H_{32}NO_4$ 422.2331 found 422.2326.

(*ent*-8). It was prepared from ***ent*-7** (135 mg, 0.33 mmol), following the same procedure described for the preparation of **8**, with similar yield (196 mg, 72%) and identical characterization data**,** except for the optical rotation: $[\alpha]_D^{20}$ + 52 (c 5.81, $CHCl_3$).

(14a*R*)-10-benzyl-2,3,6,7-tetramethoxy-14a-methyl-9,10,11,12,13,14,14a,15-octahydrodibenzo[f,h]pyrido[1,2-b]isoquinolin-10-ium bromide (9). To a solution of **8** (362 mg, 0.86 mmol) in dry CH_2Cl_2 (9.8 mL), were sequentially added K_2CO_3 (264 mg, 1.89 mmol) and benzyl bromide (114 µL, 0.95 mmol) and the reaction mixture was stirred at 25 ºC overnight. Afterwards, the mixture reaction was filtrated and the organic layer was concentrated to dryness. The residue was purified by flash column chromatography (95:5 to 9:1 $CHCl_3$/ MeOH), to obtain the desired product as an orange solid (508 mg, > 99%): $[\alpha]_D^{20}$ – 82.0 (c 7.34, $CHCl_3$); R_f 0.36 (9:1 $CHCl_3$/MeOH); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.88 (br s, 2H), 7.41 – 7.30 (m, 2H), 7.27 – 7.12 (m, 2H), 7.01 (br s, 1H), 6.96 – 6.81 (m, 2H), 5.15 (br d, *J* = 13.5 Hz, 2H), 4.56 (d, *J* = 17.3 Hz, 1H), 4.31 (d, *J* = 13.0 Hz, 1H), 4.16 (s, 6H), 4.14 – 4.07 (m, 3H), 3.99 – 3.91 (m, 3H), 3.68 (d, *J* = 18.4 Hz, 1H), 3.51 – 3.33 (m, 2H), 2.81 – 2.63 (m, 1H), 2.60 – 2.37 (m, 1H), 2.35 – 1.93 (m, 5H), 1.84 (s, 3H);^{13}C NMR (75 MHz, $CDCl_3$) δ 150.0 (*C*), 149.9 (*C*), 149.8 (*C*), 149.6 (*C*), 132.7 (2*C*H + *C*), 131.0(*C*H), 129.4(2*C*H), 126.9 (*C*), 124.8 (*C*), 124.4 (*C*), 124.2 (*C*), 122.3 (*C*), 122.2 (*C*), 118.2 (*C*), 104.0 (*C*H), 103.7 (*C*H), 103.6 (*C*H), 103.1 (*C*H), 68.0 (*C*), 56.9 (*C*H_3), 56.5 (*C*H_3), 56.3 (*C*H_3), 56.2 (*C*H_3), 54.9 (*C*H_2), 54.1 (*C*H_2), 53.5 (*C*H_2), 37.4 (*C*H_2), 32.7 (*C*H_2), 21.9 (*C*H_3), 20.3 (*C*H_2), 17.7(*C*H_2); HRMS (ESI) cald for $C_{33}H_{38}NO_4$ 512.2801 found 512.2799.

(*ent*-9). It was prepared from ***ent*-8** with similar yield (112 mg, 91 %) and identical characterization data, except for the optical rotation: $[\alpha]_D^{20}$ + 86.6 (c 6.33, $CHCl_3$).

(9*S*,14a*R*)-9-benzyl-2,3,6,7-tetramethoxy-14a-methyl-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline (10). In a dry two-necked round-bottom flask, equipped with a condenser, was added NaH (60% mineral oil dispersion, 188.0 mg, 7.85 mmol). The solid was washed twice with hexane, removing the solvent and drying the solid with cycles of vacuum/ Argon, before dry DMSO (8 mL) was added. The mixture was heated to 60 ºC during 2 h until the evolution of gases (H_2) ceased and complete dissolution of solids was observed. At this point, compound **9** (224.5 mg, 0.38 mmol) was added and the mixture was stirred 5 h at 25 ºC, before being quenched with H_2O (15 mL). The resulting white precipitate was filtrated, washed with water and dried under vacuum. The obtained solid was purified by flash column chromatography (100% $CHCl_3$ to 99: 1 $CHCl_3$/ *i*-PrOH) to obtain the desired product as pale yellow foam solid (102 mg, 52%): $[\alpha]^D_{20}$ – 154.5 (c 5.95, $CHCl_3$); R_f 0.28 (99: 1 $CHCl_3$/ ^{i}PrOH); 95:5 er according to chiral HPLC analysis [t_R (minor) 7.67 min, t_R (major) 8.43 min, see ESI for details]; ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.89 (s, 1H), 7.85 (s, 1H), 7.40 (s, 1H), 7.09 (s, 1H), 6.99 (ddd, *J* = 6.3, 3.7, 1.3 Hz, 1H), 6.96 – 6.86 (m, 2H), 6.63 – 6.56 (m, 2H), 4.37 (t, *J* = 3.7 Hz, 1H), 4.14 (s, 3H), 4.12 (s, 3H), 4.04 (s, 3H), 4.00 (s, 3H), 3.15 (dd, *J* = 13.1, 4.1 Hz, 1H), 3.07 – 2.94 (m, 2H), 2.74 – 2.58 (m, 2H), 1.93 (d, *J* = 15.1 Hz, 1H), 1.78 – 1.59 (m, 6H), 0.76 (s, 3H).^{13}C NMR (75 MHz, $CDCl_3$) δ 148.8 (*C*), 148.6 (2*C*), 148.2 (*C*), 139.0 (*C*), 130.6(2*C*H), 128.7(*C*), 128.3 (*C*), 126.7(2*C*H), 125.62(*C*), 125.6(*C*H), 124.1(*C*), 123.9(*C*), 123.5(*C*), 104.9(*C*H), 104.3(*C*H), 104.0(*C*H), 103.5(*C*H), 60.0(*C*H), 56.2(2*C*H_3), 56.1(*C*H_3), 56.0(*C*H_3), 51.2(*C*), 46.9(*C*H_2), 41.9(*C*H_2), 41.1(*C*H_2), 40.1(*C*H_2), 26.8(*C*H_2), 20.9(*C*H_2), 13.9(*C*H_3). HRMS (ESI) cald for $C_{33}H_{38}NO_4$ 512.2801 found 512.2794.

(*ent*-10). It was prepared from ***ent*-9** with similar yield (12 mg, 45%) and identical data as **10** except for the optical rotation: $[\alpha]_D^{20}$ + 155.2 (c 4.50, $CHCl_3$).

Acknowledgements

We thank the Spanish Ministerio de Ciencia e Innovación (CTQ2011-24165) and to the University of Alicante (VIGROB-173) for financial support. C. A.-T. thanks the ISO for a grant.

Notes and references

1 (a) X. H. Qian, P. W. Lee and S. Cao, *J. Agric. Food Chem.*, 2010, **58**, 2613; (b) J. N. Seiber, *J. Agric. Food Chem.*, 2011, **59**, 1.

2 (a) D. E. Lande, *Aust. J. Exp. Biol. Med. Sci.*, 1948, **34**, 181; (b) N. R. Famsworth, N. K. Hart, S. R. Johns, J. A. Lanberton and W. Messmer, *Aust. J. Chem.*, 1969, **22**, 1805; (c) Y. Luo, Y. Liu, D. Luo, X. Gao, B. Li and G. Zhang, *Planta Medica*, 2003, **69**, 842.

3 J. Yan, D. Luo, Y. Luo, X. Gao and G. Zhang, *Int. J. Gynecol. Cancer*, 2006, **16**, 165.

4 (a) Y.-Z. Lee, C.-W. Yang, H.-Y. Hsu, Y.-Q. Qiu, T.-K. Yeh, H.-Y. Chang, Y.-S. Chao and S.-J. Lee, *J. Med. Chem.*, 2012, **55**, 10363. (b) Z. Wang, M. Wu, Y. Wang, Z. Li, L. Wang, G. Han, F. Chen, Y. Liu, K. Wang, A. Zhang, L. Meng and Q. Wang, *Eur. J. Med. Chem.*, 2012, **51**, 250.

5 M. S. Christodoulou, F. Calogero, M. Baumann, A. N. García-Argáez, S. Pieraccini, M. Sironi, F. Dapiaggi, R. Bucci, G. Groggini, S. Gazzola, S. Liekens, A. Silvani, M. Lahtela-Kakkonen, N. Martinet, A. Nonell-Canals, E. Santamaría-Navarro, I. R. Baxendale, L. Dalla Via and D. Passarella, *Eur. J. Med. Chem.*, 2015, **92**, 766.

6 G. R. Pettit, A. Goswami, G. M. Cragg, J. M. Schmit and J. C. Zou, *J. Nat. Prod.*, 1984, **47**, 913.

7 M. Ishikawa and Y. Hashimoto, *J. Med. Chem.*, 2011, **54**, 1539.

8 M. Suffness, J. Douros, in *Anticancer Agents Based on Natural Product Models,* ed. J. M. Cassady, J. D. Douros, Academic Press: London, 1980; pp 465-487.

9 (a) B. Su, C. Cai and Q. Wang, *J. Org. Chem.*, 2012, **77**, 7981; (b) B. Su, M. Deng and Q. Wang, *Eur. J. Org. Chem.*, 2013, 1979.

10 (a) T.-H. Chuang, S.-J. Lee, C.-W. Yang and P.-L. Wu, *Org. Biomol. Chem.*, 2006, **4**, 860; (b) C. W. Yang, T. H. Chuang, P. L. Wu, W. H. Huang and S. J. Lee, *Biochem. Biophys. Res. Commun.*, 2007, **354**, 942; (c) Y.-Z. Lee, C.-W. Yang, H.-Y. Hsu, Y.-Q. Qiu, T.-K. Yeh, H.-Y. Chang, Y.-S. Chao and S.-J. Lee, *J. Med. Chem.*, 2012, **55**, 10363; (d) Z. Wang, A. Feng, M. Cui, Y. Liu, L. Wang and Q. Wang, *Chem. Biol. Drug Des.*, 2014, **84**, 531.

11 For previous examples from our group on the transformation of chiral homoallylic sulfinamines into alkaloid derivatives, see: (a) M. Medjahdi, J. C. Gonzalez-Gomez, F. Foubelo and M. Yus, *Eur. J. Org. Chem.*, 2011, 2230; (b) I. Bosque, J. C. Gonzalez-Gomez, A. Guijarro, F. Foubelo and M. Yus, *J. Org. Chem.*, 2012, **77**, 10340; (c) I. Bosque, J. C. Gonzalez-Gomez, M. I. Loza and J. Brea, *J. Org. Chem.*, 2014, **79**, 3982; (d) C. Anton-Torrecillas and J. C. Gonzalez-Gomez, *Org. Biomol. Chem.*, 2014, **12**, 7018.

12 The use of chiral homoallylic sulfinamines in the synthesis of phenanthroizidine alkaloids has also been nicely illustrated by other research group, see: Y. Zheng, Y. Liu and Q. Wang, *J. Org. Chem.*, 2014, **79**, 3348.

13 We have recently reported the successful application of this methodology in the synthesis of (*R*)- and (*S*)-7-methoxycryptopleurine, see: C. Anton-Torrecillas, I. Bosque, J. C. Gonzalez-Gomez, M. I. Loza and J. Brea, *J. Org. Chem.*, 2015, **80**, 1284.

14 The corresponding 9-bromo-2,3,6,7-tetramethoxy-phenanthrene was prepared by: (a) Perkin condensation of homoveratric acid and veratraldehyde, followed by oxidative coupling mediated by $FeCl_3$, according to: K-L. Wang, M-Y. Lü, Q-M. Wang and R-Q. Huang, *Tetrahedron*, 2008, **64**, 7504; (b) Decarboxylation with $CuSO_4$ in quinoline afforded the corresponding phenanthrene: J. E. Nordlander and F. G. Njoroge, *J. Org. Chem.*, 1987, **52**, 1627; (c) Halogenation with NBS afforded the corresponding aryl bromide derivative, according to: L. M. Rossiter, M. L. Slater, R. E. Giessert, S. A. Sakwa and R. J. Herr, *J. Org. Chem.*, 2009, **74**, 9554.

15 (a) P. A. Bradley, R. J. Carroll, Y. C. Lecouturier, R. Moore, P. Noeureuil, B. Patel, J. Snow and S. Wheeler, *Org. Process Res. Dev.*, 2010, **14**, 1326; (b) P. A. Glossop, C. A. L. Lane, D. A. Price, M. E. Bunnage, R. A. Lewthwaite, K. James, A. D. Brown, M. Yeadon, C. Perros-Huguet, M. A. Trevethick, N. P. Clarke, R. Webster, R. M. Jones, J. L. Burrows, N. Feeder, S. C. J. Taylor and F. J. Spence, *J. Med. Chem.*, 2010, **53**, 6640; (c) N. Kosugi, M. Suzuki, I. Hagiwara, K. Goto, K. Saitoh and T. Migita, *Chem. Lett*., 1982, 939.

16 An authentic diastereomeric mixture of compound **4** was prepared by epimerization of the sulfur atom, according to a reported procedure: K. Brak, K. T. Barret and J. A. Ellman, *J. Org. Chem.*, 2009, **74**, 3606. This procedure allowed to unequivocally assigning characteristic peaks of the minor diastereoisomer in the ^{1}H-NMR spectra (see ESI).

17 (a) J. A. Sirvent, F. Foubelo and M. Yus, *Chem. Commun*. 2012, **48**, 2543; (b) I. Bosque, E. Bagdatli, F. Foubelo and J. C. Gonzalez-Gomez, *J. Org. Chem.,* 2014, **79**, 1796.

18 The configuration of the new stereogenic center was assigned to be *R* on the basis of a stereochemical model previously proposed for this reaction (References 17 and 19). The predictive value of this model has been successfully used in the synthesis of other natural compounds with known stereochemistry (some examples in reference 11).

19 (a) J. C. Gonzalez-Gomez, M. Medjahdi, F. Foubelo and M. Yus, *J. Org. Chem*., 2010, **75**, 6308; (b) J. C. Gonzalez-Gomez, F. Foubelo and M. Yus, *Org. Synth.*, 2012, **89**, 88.

20 (a) G. Makado, T. Morimoto, Y. Sugimoto, K. Tsutsumi, N. Kagawa and K. Kakiuchi, *Adv. Synth. Catal.*, 2010, **352**, 299; (b) E. Cini, E. Airiau, N. Girard, A. Mann, J. Salvadori and M. Taddei, *Synlett*, 2011, 199; (c) H. Ren and W. D. Wulff, *Org. Lett.*, 2013, **15**, 242.

21 For some examples that made use of Pictet-Spengler anulation of D ring in phenanthroizidines, see: (a) W. Zeng and S. R. Chemler, *J. Org. Chem.*, 2008, **73**, 6045; (b) M. B. Cui, H. J. Song, A. Z. Feng, Z. W. Wang and Q. M. Wang, *J. Org. Chem.* 2010, **75**, 7018; (c) D. N. Mai and J. P. Wolfe, *J. Am. Chem. Soc.*, 2010, **132**, 12157.

22 Z. Wang, A. Feng, M. Cui, Y. Liu, L. Wang and Q. Wang, *Plos ONE*, 2012, **7**, e52933.

23 Q. Wang, C. Wang, A. Feng, L. Wang, Y. Liu and M. Cui, *PCT Int. Appl.*, 2014, **WO 2014000586A1** 20140103.

24 The Stevens rearrangement has been recently used for the preparation of phenanthroindolizidines, see: (a) G. Lahm, A. Stoye and T. Opatz, *J. Org. Chem.*, 2012, **77**, 6620; (b) Q.-X. Lin and T.-L. Ho, *Tetrahedron*, 2013, **69**, 2996.

25 M. Valpuesta, A. Diaz, G. Torres and R. Suau, *Tetrahedron*, 2002, **58**, 5053.

26 W. D. Ollis, M. Rey, I. O. Sutherland, *J. Chem. Soc., Perkin Trans I,* 1983, 1009.

27 (a) M. Valpuesta, A. Diaz, R. Suau and G. Torres, *Eur. J. Org. Chem.*, 2004, 4313; (b) M. Valpuesta, M. Ariza, A. Diaz, G. Torres and R. Suau, *Eur. J. Org. Chem.*, 2010, 638.